PDCD1 and non-small cell lung carcinoma: Multiple phase III trials for advanced melanoma, renal cell carcinoma and non-small cell lung cancer (NSCLC) have shown better clinical outcomes for anti-PD-1 antibody than conventional treatment [4–6].